Compare SCHL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | ARVN |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.4M | 658.2M |
| IPO Year | 1995 | 2018 |
| Metric | SCHL | ARVN |
|---|---|---|
| Price | $45.46 | $7.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $40.00 | $15.05 |
| AVG Volume (30 Days) | 295.2K | ★ 678.1K |
| Earning Date | 03-19-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,487,100,000.00 | $262,600,000.00 |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $23.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.60 | $6.06 |
| 52 Week High | $44.54 | $14.22 |
| Indicator | SCHL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 44.44 |
| Support Level | $37.84 | $7.35 |
| Resistance Level | N/A | $10.18 |
| Average True Range (ATR) | 1.28 | 0.41 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 98.63 | 62.25 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.